Rybelsus
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Rybelsus in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Rybelsus.
27
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Rybelsus
The reduction in price to $675 will take effect at the beginning of next year
The deal includes a CB1 blocker being developed to treat metabolic syndrome and its associated complications
The deal marks a significant boost to the company’s cardiometabolic disease pipeline
Semaglutide is already available in major markets as a once-weekly injection
Semaglutide works by mimicking an intestinal hormone that is released after eating
Rybelsus was initially approved in 2019 as a second-line treatment
Lilly’s drug beat semaglutide 1mg on multiple measures including weight loss
Danish pharma will acquire all outstanding shares in Emisphere
Why driving behaviour change is the next big focus for pharma companies in chronic diseases
The latest Cortellis Drugs to Watch report highlights medicines that treat high prevalence conditions
Company says it will work towards value-based agreements for the drug
Approved for risk reduction in primary and secondary populations
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology